Open interest declined by a large amount? They mush have bought them back yesterday, I was not keeping a close eye on volume. Nice start!
I have talked to some fairly senior level commercial people recently (marketing, market research, sales, not Bus Dev) that work for large pharma and are expecting a decline in sales, downsizing at their current employer. I asked them all, why not just buy ACAD and grow your way out? Big pharma would be crazy not to buy, or partner with ACAD, they all need growth and new products and many have a sales force that could easily be trained.
Selling Pima might not need a large presence of salespeople on the ground as much as people working with managed markets, insurance, payers, etc. I guess the positive for ACAD if they want to go alone is, they should be able to quickly attract qualified people to market and sell a neuroscience product.
and 1 largest sales related to VVUS. Looks like it will be very expensive for shorts and option players to manage a $5 close today. Tele is working hard. Maybe $5.5 on a good script number today?
yes, I have been telling my stock-averse sig other that for years, she is waiting for those 5% CD's to return. Will ACAD close at $23, closest strike on Friday?
easy, they said 2 years on the c-call. They must be planning on very slow enrollment.
I like decider, but I can't claim victory in the price rise from $4-5. When we get to $8 I will send JL flowers, or maybe Cindy.
they have been doing a great job of keeping the price low for most of the past 20+ years except for a few brief spikes. IMGN could be the golden goose in the right hands! The new technology sounds interesting. John deserves to work with someone that can get his great work to patients and build shareholder value and DJ is not the guy.
most sales over the past year have been very timely, see chart...upper left to lower rt. $5 tomorrow, then hopefully, finally back to the plus side. I was hoping we would lose some shorts that sold calls, but apparently they are not ready to leave just yet.
IMGN has a product, good technology, cash, licensing deals and at least one very interesting wholly owned molecule 289. What they lack is strong management, leadership, strength in advanced drug development. SGEN could buy them cheap, IMGN shareholders would love to have SGEN stock and better management. I will take 1 for 2 right now. Let's get this deal done, combine forces and rule the ADC market!
sure, there's more where the other cheap options came from, they just keep granting them. Poor Spector is so underpaid, he could never make it on that $686k salary, probably needs a moat for his San Diego castle. Those options had a lot of time remaining. The insider selling is getting old. Heading to $5 tomorrow it appears. Sad they are helping the shorts out.
wondering if DJ is in hiding and fed Charlie to the wolves, but hoping he's on his way out. Let's see who presents next. Charlie is obviously inexperienced at presenting on business issues, needs more practice. Hope he listens to the cc replay learns and prepares more if there is a next time.
Charlie needs to slow down and speak more clearly.
The best comment I heard from the call came from the analyst who asked...why would you use anything other than the proven linker and Dm1, so basically why not become a factory, take antibody, add the same linker and killing agent proven to work in Kadcyla and crank out successful new products. I believe CH and a few other smart posters have made a similar argument. Don't get cute, don't over think, do what works.
The most stupid comment was that they would announce a decision on 901 next week, so apparently they intend to talk more about the failure. Here's an idea STHU about 901, let it die a silent death, move on, start applying the proven technology to enhance other antibodies through partners, it's a no brainer!!!
Let John and his team focus on the new technology and do new licensing deals for every active antibody using proven Kadcyla technology and let the partner do the development work since you can't develop.
Finally, the BT drug looks interesting. Buy in at the low cost and license your rights out to the highest bidder for a profit. Another no-brainer. This business should be printing cash if run properly. Instead we have a bunch of brain-dead, self serving dopes in control. I feel bad for John Lambert and co, he's the only one adding value then the dopes in charge screw things up.
unfortunately, these are not buys, they are the BOD stealing cheap, free shares for doing NOTHING. We should report this suspicous timing to the SEC, I am getting tired ot their terrible corp. governance!
he's simply a hedge fund tool. He has learned just enough to be dangerous and sound like he know what he's talking about. He has learned a few things about the FDA through experience. He's had a few good calls, but nothing he says is original thinking. He hears from his hedge fund friends that are talking their book and parrots their call. If we can ever link his calls to compensation, he will be put away and maybe take down his boss, Cramer the clown. I have tried to like him and give him the benefit of the doubt, but the recent hatchet job he did on IMGN was such a blatant misrepresentation of the facts and truth, I am now happy to see him rot in jail with his criminal bio-short hedge fund buddies. All IMO of course I have no specific proof that he's a criminal, just a strong suspicion.
Feel free to add your comments about the AF SRPT debacle call by AF on FierceBiotech. That clown deserves to rot in jail for his crimes against biotech investors IMO + a sprinkle of half truths to avoid saying anything for which I can be prosecuted of course.
Not sure about that, but SRPT blow up might have got management's attention. FDA approval and drug launch is risky business for a small biopharma. If they can get a good offer in the $30's now, they should consider it. IMO, long and hopeful, but experienced enough in biotech to know risk is not low.
The CEO has zero communication skills. They once employed a senior level, strategic thinking IR pro David Wallsey and apparently downsized him at some point and kept the manager, professional ball girl instead. Now she's the VP of IR. She's a nice and attractive young lady, she's learning and growing, but not at the level of David, or other industry execs. Maybe Jack does not want a strong IR pro and prefers someone more junior that will not stand up to him. He prefers a weak CFO. Just a theory.